Lupus, an autoimmune disorder, presents skin manifestations like the butterfly rash, often mimicked by conditions such as ...

Lupus can be debilitating and sometimes deadly for the 3 million people who have it. A treatment called CAR T appears to stop ...

WILLOW (NCT05162586) is a randomized, double-blind, placebo-controlled Phase 2 proof of concept and dose-finding study designed to evaluate the efficacy and safety of enpatoran in patients with ...

Advanced practice providers can play a key role in providing patients with chronic lymphocytic leukemia with autoimmune disease testing and referring them to rheumatology when appropriate.

Inflammation affects up to 93% of people diagnosed with lupus, and red spots and butterfly rashes are the first sign in up to 25% of people with the disease. ... Mortality in systemic lupus ...

A malar rash (butterfly rash) is a classic early sign of lupus. Typically triggered by exposure to sunlight, it is often the first visible sign of lupus. ... Systemic lupus erythematosus (lupus).

The U.S. Food & Drug Administration (FDA) has granted approval for a new subcutaneous autoinjector formulation of belimumab ...

Researchers from EMD Serono and global collaborators shared promising results from Cohort B of the phase II trial of the WILLOW study.

Symptoms of systemic lupus erythematosus (SLE) must be brought under control to avert immediate consequences and afford the patient a better quality of life. Damage resulting from the disease and ...

The American College of Rheumatology has updated its systemic lupus erythematosus treatment guidelines for the first time ...